Kristen B. Slaoui

Vice President Head of North America Business Development at GlaxoSmithKline plc

Location:
5 Crescent Drive, Philadelphia, Pennsylvania, United States
Company:
GlaxoSmithKline plc
HQ Phone:
(215) 751-4000
Wrong Kristen Slaoui?

Last Updated 7/11/2017

General Information

Education

University of Washington

Bachelor's degrees  - Biology and Classical Studies , Gettysburg College

Ph.D.  - Physiology , The Johns Hopkins Bloomberg School of Public Health

doctoral degree  - physiology , The Johns Hopkins University Bloomberg School of Public Health

Affiliations

Executive Board Member  - The Grayson School

Adjunct Assistant Professor  - Johns Hopkins University

Web References  

http://thegraysonschool.org/about-us/executive-board

Dr. Kristen B. Slaoui, Ph.D.: is Vice President of Corporate Development and Strategy for GlaxoSmithKline (GSK), and the Head of Business Development and Licensing with Stiefel, a specialty dermatology company and part of GSK.
She has spent fourteen years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the active agent in the recently approved medicines Anoro™ Ellipta™ and Incruse™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and has an ongoing role as a peer reviewer for a dozen established medical journals. Since joining GSK's Business Development teams in 2006, she has executed nearly $11 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories. Dr. Slaoui earned Bachelor's degrees in both Biology and Classical Studies from Gettysburg College. After winning a pre-doctoral Research Training Fellowship grant award from the National Institutes of Environmental Health Sciences of the National Institutes of Health (NIH), she earned her Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health, where she was an NIH Pre-Doctoral Fellow. Following conferral of her degree, she won an NIH Post-Doctoral Fellowship at the University of Washington. After her term in Seattle, she accepted a position in Respiratory Drug Discovery at GSK, but continued her commitment to academic research by spending over a decade as an adjunct assistant professor at her alma mater, The Johns Hopkins Bloomberg School of Public Health in Baltimore, MD.

Read More
Speakers § The Inaugural Dermatology Summit

Kristen Slaoui, Ph. D.
Kristen Slaoui, Ph. D. Vice President, Business Development & Licensing, Stiefel, a GSK Company Kristen Belmonte Slaoui joined Stiefel, a GSK company, in March 2010 as Director of Business Development and Licensing. Prior to her current role, she was part of the GSK Corporate Development team where she led the acquisition of Stiefel Laboratories in 2009. Kristen spent several years in GSK's Worldwide Business Development team leading Business Development & Licensing efforts in Immuno-inflammation. During this time, she was responsible for closing several significant deals for GSK, such as those with Genmab (Arzerra™), Tolerx (Toliva™), Cellzome, Regulus and Dynavax, and the acquisition of Praecis. Kristen also has six years experience in drug discovery in Neuroscience at Merck Research Laboratories and in Respiratory at GSK, where she led discovery efforts for the long acting muscarinic receptor antagonists ("LAMAs") which are now undergoing FDA review. She holds a doctoral degree in Physiology from The Johns Hopkins University Bloomberg School of Public Health, where she has been an adjunct assistant professor since 2001. She completed postdoctoral studies in Neuroscience at the University of Washington in Seattle, and is the author of more than 40 original publications and patents.

Read More
The Inaugural Dermatology Summit

Kristen Slaoui, Ph. D.
Kristen Slaoui, Ph. D. Vice President, Business Development & Licensing, Stiefel, a GSK Company

Read More

Browse ZoomInfo’s Directories